VENCLEXTA  + azacitidine (VEN + AZA)

VENCLEXTA + decitabine (VEN + DEC)

VENCLEXTA + low-dose cytarabine (VEN + LDAC)

CR=complete remission; CRh=complete remission with partial hematologic recovery; FLT3=fms-like tyrosine kinase 3; IDH=isocitrate dehydrogenase; NPM=nucleophosmin; RBC=red blood cell; TP53=tumor protein p53.

*Patients who achieved transfusion independence regardless of response. Patients may have achieved transfusion independence and not achieved a CR or CRh during VENCLEXTA therapy. n=patients who achieved transfusion independence; N=patients transfusion dependent at baseline.

Post-baseline transfusion evaluation period is from the first dose of study drug and the last dose of study drug + 30 days, or disease progression (including clinical progression), or death, or data versioning date, whichever occurred earlier.